A drug trial for a Merck & Co Inc. (MSD) medication verubecestat has been stopped because it was very unlikely to show a significant difference in Alzheimers disease progression compared to a placebo control. This was a phase III clinical trial in patients with early dementia. The setback comes after months of positive media attributed … [Read more...] about Failed trials for Alzheimer’s may mean a key theory is wrong
Worrying reports have surfaced regarding Trump’s new healthcare secretary and his views on anti-vaccination. Tom Price now heading a department backed by a budget of over $1 trillion USD, is a member of a group that describes mandatory vaccination as “equivalent to human experimentation”. The group itself, the Association of American Physicians and … [Read more...] about Donald Trump’s stance on anti-vaccination
Hyderus undertakes healthcare research in Argentina Hyderus was recently commissioned to undertake research into the market for innovative oncology products in Argentina, which is an emerging country in terms of its healthcare status on the world stage. An in-depth research project was undertaken, which looked at the Argentine health system, … [Read more...] about Patagonia/Argentina – what’s our connection?
Hyderus - It’s all about Community Since Hyderus first arrived in the small Welsh village of Cwmfelinfach some sixteen years ago, it has been very keen to invest and support the local community and wider area. Investment in local businesses has been one of the company’s priorities and playing an important role in community life is integral to … [Read more...] about Hyderus – it’s all about Community!
A separate article which is included in PME and written exclusively by Mark Chataway, summarises the “Five Myths about emerging markets”. Mark challenges the current thinking with his fact-defying answers to the following statements : You can have an ‘emerging markets strategy’ Mark stresses that emerging markets are intrinsically … [Read more...] about Mark’s five myths about emerging markets made simple!
Mark Chataway featured in an article by Chris Ross (a freelance writer specialising in the pharmaceutical and healthcare industry) about emerging markets in PME (Pharmaceutical Market Europe), July/August 2015. Pharmaceutical Market Europe is a monthly print and digital title written by experienced journalists and high-profile pharmaceutical and … [Read more...] about Hyderus making tidal waves in the world of pharmaceutical journalism!
Hyderus has enjoyed a very fruitful twelve months and, in this blog, I would like to look at the type of work being undertaken by the company during the last year and give you an overview of the diverse areas of business in which Hyderus becomes involved. We have been working on several projects this year, spanning all continents and involving … [Read more...] about Hyderus making bigger waves!!
Hyderus and Toilet Twinning Hyderus has recently twinned its toilets with those in Bihar, India, establishing two separate toilets through the Tearfund and Cord charities as part of their drive to build more toilets in countries with poor hygiene and sanitation. When twinning toilets, there are several countries to choose from, mostly in … [Read more...] about Hyderus causing a stink!
Gwnaeth Mark Chataway ac ei gwmni e, Hyderus, ymddangos yn rhifyn Awst/Medi o’r cylchgrawn “Insider” sef cyfnodolyn busnes sy’n cwmpasu Cymru gyfan sy’n atynnu darllenwyr busnes dylanwadol y wlad. Mae’r erthygl o’r teitl “Mwy i’w gynnig” yn edrych ar wahanol gwmnïau sy wedi eu lleoli yng Nghymoedd De Cymru a sut y maent yn llwyddo mewn ardal sy’n … [Read more...] about More Publicity for Hyderus
Mae cylchlythyr a gyhoeddwyd gan y cylchgrawn Insider (cylchgrawn busnes Cymreig allweddol gyda llawer o ddarllenwyr dylanwadol yng Nghymru) yn cynnwys erthygl am gytundeb yn India a enillodd Hyderus ym mis awst 2013. Aeth yr erthygl ymlaen i amlinellu pwrpas y cytundeb, y nod yn bennaf yw helpu oresgyn rhwystrau i imiwneiddio yn India a fydd yn … [Read more...] about Cyhoeddusrwydd i Hyderus wrth ennill cytundeb Indiaidd/ Publicity for Hyderus as it wins Indian Contract